These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 7683570

  • 1. Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity.
    Rhee MS, Wang Y, Nair MG, Galivan J.
    Cancer Res; 1993 May 15; 53(10 Suppl):2227-30. PubMed ID: 7683570
    [Abstract] [Full Text] [Related]

  • 2. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
    Rhee MS, Galivan J, Wright JE, Rosowsky A.
    Mol Pharmacol; 1994 Apr 15; 45(4):783-91. PubMed ID: 7514264
    [Abstract] [Full Text] [Related]

  • 3. Effects of gamma-glutamyl hydrolase on folyl and antifolylpolyglutamates in cultured H35 hepatoma cells.
    Yao R, Rhee MS, Galivan J.
    Mol Pharmacol; 1995 Sep 15; 48(3):505-11. PubMed ID: 7565632
    [Abstract] [Full Text] [Related]

  • 4. Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
    Galivan J, Nimec Z, Rhee M, Boschelli D, Oronsky AL, Kerwar SS.
    Cancer Res; 1988 May 01; 48(9):2421-5. PubMed ID: 2965613
    [Abstract] [Full Text] [Related]

  • 5. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
    Pizzorno G, Moroson BA, Cashmore AR, Russello O, Mayer JR, Galivan J, Bunni MA, Priest DG, Beardsley GP.
    Cancer Res; 1995 Feb 01; 55(3):566-73. PubMed ID: 7834626
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Secretion of gamma-glutamyl hydrolase in vitro.
    O'Connor BM, Rotundo RF, Nimec Z, McGuire JJ, Galivan J.
    Cancer Res; 1991 Aug 01; 51(15):3874-81. PubMed ID: 1713122
    [Abstract] [Full Text] [Related]

  • 11. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
    Liani E, Rothem L, Bunni MA, Smith CA, Jansen G, Assaraf YG.
    Int J Cancer; 2003 Feb 20; 103(5):587-99. PubMed ID: 12494465
    [Abstract] [Full Text] [Related]

  • 12. Glutamyl hydrolase: properties and pharmacologic impact.
    Galivan J, Ryan T, Rhee M, Yao R, Chave K.
    Semin Oncol; 1999 Apr 20; 26(2 Suppl 6):33-7. PubMed ID: 10598552
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration.
    Jansen G, Barr H, Kathmann I, Bunni MA, Priest DG, Noordhuis P, Peters GJ, Assaraf YG.
    Mol Pharmacol; 1999 Apr 20; 55(4):761-9. PubMed ID: 10101035
    [Abstract] [Full Text] [Related]

  • 17. Biochemical and growth inhibitory effects of the erythro and threo isomers of gamma-fluoromethotrexate, a methotrexate analogue defective in polyglutamylation.
    McGuire JJ, Graber M, Licato N, Vincenz C, Coward JK, Nimec Z, Galivan J.
    Cancer Res; 1989 Aug 15; 49(16):4517-25. PubMed ID: 2472880
    [Abstract] [Full Text] [Related]

  • 18. Gamma-glutamyl hydrolase and drug resistance.
    Schneider E, Ryan TJ.
    Clin Chim Acta; 2006 Dec 15; 374(1-2):25-32. PubMed ID: 16859665
    [Abstract] [Full Text] [Related]

  • 19. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport.
    Matherly LH, Angeles SM, McGuire JJ.
    Biochem Pharmacol; 1993 Dec 14; 46(12):2185-95. PubMed ID: 7506026
    [Abstract] [Full Text] [Related]

  • 20. The role of cellular folates in the enhancement of activity of the thymidylate synthase inhibitor 10-propargyl-5,8-dideazafolate against hepatoma cells in vitro by inhibitors of dihydrofolate reductase.
    Galivan J, Rhee MS, Johnson TB, Dilwith R, Nair MG, Bunni M, Priest DG.
    J Biol Chem; 1989 Jun 25; 264(18):10685-92. PubMed ID: 2525127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.